GLP-1 diabetes drugs linked to up to 68% higher hair loss risk
A study published in The BMJ suggests that GLP-1 receptor agonists, commonly used for type 2 diabetes and obesity, are linked to a higher risk of hair loss. Researchers compared patient data from over 27,000 individuals to determine the association between these medications and alopecia.
Why it matters
As the popularity of weight-loss and diabetes drugs like semaglutide grows, understanding potential side effects is crucial for patients and doctors making informed treatment decisions.
edited by Sadie Harley , reviewed by Andrew Zinin
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Credit: Pavel Danilyuk from Pexels The use of glucagon-like peptide-1 (GLP-1) receptor agonists to treat type 2 diabetes and obesity is associated with an increased risk of hair loss (alopecia) in adults with type 2 diabetes, a study published by The BMJ finds. Although the absolute risk is low, awareness of this potential effect may help inform shared treatment decisions, the researchers say.
Alopecia has been reported as a possible side effect of GLP-1 receptor agonists, particularly semaglutide and tirzepatide. However, studies assessing the risk of alopecia associated with GLP-1 receptor agonists compared with other diabetes drugs are lacking.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in